EUVIMEDEUVIMED entdecken
Open Access

Modeling SMAD2 Mutations in Induced Pluripotent Stem Cells Provides Insights Into Cardiovascular Disease Pathogenesis

Tarsha Ward iD, Sarah U Morton iD, Gabriela Venturini iD, Warren Tai iD, Min Young Jang, Joshua Gorham iD, Dan Delaughter iD, Lauren K Wasson iD, Zahra Khazal iD, Jason Homsy, Bruce D Gelb iD, Wendy K Chung iD und 6 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.036860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Tarsha Ward und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics Harvard Medical School Boston MA USA. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Smad2 Protein, Heart Defects, Congenital, Myocytes, Cardiac. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SMAD2 is a coregulator that binds a variety of transcription factors in human development. Heterozygous SMAD2 loss‐of‐function and missense variants are identified in patients with congenital heart disease (CHD) or arterial aneurysms. Mechanisms that cause distinct cardiovascular phenotypes remain unknown. We aimed to define transcriptional and epigenetic effects of SMAD2 variants and their role in CHD. We also assessed the function of SMAD2 missense variants of uncertain significance. Methods and Results Rare SMAD2 variants (minor allele frequency ≤10 −5 ) were identified in exome sequencing of 11 336 participants with CHD. We constructed isogenic induced pluripotent stem cells with heterozygous or homozygous loss‐of‐function and missense SMAD2 variants identified in CHD probands. Wild‐type and mutant induced pluripotent stem cells were analyzed using bulk RNA sequencing, chromatin accessibility (Assay for Transposase‐Accessible Chromatin With Sequencing), and integrated with published SMAD2/3 chromatin immunoprecipitation data. Cardiomyocyte differentiation and contractility were evaluated. Thirty participants with CHD had heterozygous loss‐of‐function or missense SMAD2 variants. SMAD2 haploinsufficiency altered chromatin accessibility at promoters and dysregulated expression of 385 SMAD regulated genes, including 10 CHD‐associated genes. Motifs enriched in differential Assay for Transposase‐Accessible Chromatin peaks predicted that SMAD2 haploinsufficiency disrupts interactions with transcription factors NANOG (homeobox protein NANOG), ETS, TEAD3/4 (transcriptional enhanced associate domain 3/4), CREB1 (cAMP response element binding protein 1), and AP1 (activator protein 1). Compared with SMAD2 ‐haploinsufficient cells, induced pluripotent stem cells with R114C or W274C variants exhibited distinct and shared chromatin accessibility and transcription factor binding changes.

Conclusions

SMAD2 haploinsufficiency disrupts transcription factor binding and chromatin interactions critical for cardiovascular development. Differences between the molecular consequences of loss‐of‐function and missense variants likely contribute to phenotypic heterogeneity. These findings indicate opportunities for molecular analyses to improve reclassification of SMAD2 variants of uncertain clinical significance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induced Pluripotent Stem CellsSmad2 ProteinHeart Defects, CongenitalMyocytes, CardiacMutation, MissenseHumansHaploinsufficiencyMaleEpigenesis, GeneticFemalePhenotypeCell DifferentiationExome SequencingGenetic Predisposition to DiseaseLoss of Function Mutation

Stichwörter der Autor:innen

CRISPR/Cas9 gene editingSMAD2congenital heart diseaseinduced pluripotent stem cellsmechanisms of transcriptional regulation

Substanzen

Smad2 ProteinSMAD2 protein, human

Autor:innen und Institutionen

  • Department of Genetics Harvard Medical School Boston MA USA.
  • Division of Newborn Medicine Boston Children's Hospital Boston MA USA.
  • Cardurion Pharmaceuticals, Inc. Burlington MA USA.
  • Mindich Child Health and Development Institute and the Department of Pediatrics and Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York NY USA.
  • Department of Pediatrics, Boston Children's Hospital Harvard Medical School Boston MA USA.
  • Gladstone Institutes San Francisco CA USA.

ORCID-Profile: Tarsha Ward, Sarah U Morton, Gabriela Venturini, Warren Tai, Joshua Gorham, Dan Delaughter, Lauren K Wasson, Zahra Khazal, Bruce D Gelb, Wendy K Chung, Martin Tristani-Firouzi, Steven R DePalma, Christine Seidman, J G Seidman

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Ward, T., Morton, S. U., Venturini, G., Tai, W., Jang, M. Y., Gorham, J., Delaughter, D., Wasson, L. K., Khazal, Z., Homsy, J., Gelb, B. D., Chung, W. K., Bruneau, B. G., Brueckner, M., Tristani-Firouzi, M., DePalma, S. R., Seidman, C., & Seidman, J. G. (2025). Modeling SMAD2 Mutations in Induced Pluripotent Stem Cells Provides Insights Into Cardiovascular Disease Pathogenesis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036860

Vancouver

Ward T, Morton SU, Venturini G, Tai W, Jang MY, Gorham J, et al. Modeling SMAD2 Mutations in Induced Pluripotent Stem Cells Provides Insights Into Cardiovascular Disease Pathogenesis. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.036860

BibTeX
@article{Ward2025,
  author = {Ward, Tarsha and Morton, Sarah U and Venturini, Gabriela and Tai, Warren and Jang, Min Young and Gorham, Joshua and Delaughter, Dan and Wasson, Lauren K and Khazal, Zahra and Homsy, Jason and Gelb, Bruce D and Chung, Wendy K and Bruneau, Benoit G and Brueckner, Martina and Tristani-Firouzi, Martin and DePalma, Steven R and Seidman, Christine and Seidman, J G},
  title = {Modeling SMAD2 Mutations in Induced Pluripotent Stem Cells Provides Insights Into Cardiovascular Disease Pathogenesis},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.036860}
}
Kostenlos starten →